Cargando…

High Risk of Heart Tumors after COVID-19

An emergence of evidence suggests that severe COVID-19 is associated with an increased risk of developing breast and gastrointestinal cancers. The aim of this research was to assess the risk of heart tumors development in patients who have had COVID-19. Methods: A comparative analysis of 173 heart t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitrofanova, Lubov, Makarov, Igor, Goncharova, Ekaterina, Makarova, Taiana, Starshinova, Anna, Kudlay, Dmitry, Shlaykhto, Evgeny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608002/
https://www.ncbi.nlm.nih.gov/pubmed/37895467
http://dx.doi.org/10.3390/life13102087
_version_ 1785127676100476928
author Mitrofanova, Lubov
Makarov, Igor
Goncharova, Ekaterina
Makarova, Taiana
Starshinova, Anna
Kudlay, Dmitry
Shlaykhto, Evgeny
author_facet Mitrofanova, Lubov
Makarov, Igor
Goncharova, Ekaterina
Makarova, Taiana
Starshinova, Anna
Kudlay, Dmitry
Shlaykhto, Evgeny
author_sort Mitrofanova, Lubov
collection PubMed
description An emergence of evidence suggests that severe COVID-19 is associated with an increased risk of developing breast and gastrointestinal cancers. The aim of this research was to assess the risk of heart tumors development in patients who have had COVID-19. Methods: A comparative analysis of 173 heart tumors was conducted between 2016 and 2023. Immunohistochemical examination with antibodies against spike SARS-CoV-2 was performed on 21 heart tumors: 10 myxomas operated before 2020 (the control group), four cardiac myxomas, one proliferating myxoma, three papillary fibroelastomas, two myxofibrosarcomas, one chondrosarcoma resected in 2022–2023. Immunohistochemical analysis with antibodies against CD34 and CD68 was also conducted on the same 11 Post-COVID period heart tumors. Immunofluorescent examination with a cocktail of antibodies against spike SARS-CoV-2/CD34 and spike SARS-CoV-2/CD68 was performed in 2 cases out of 11 (proliferating myxoma and classic myxoma). Results: A 1.5-fold increase in the number of heart tumors by 2023 was observed, with a statistically significant increase in the number of myxomas. There was no correlation with vaccination, and no significant differences were found between patients from 2016–2019 and 2021–2023 in terms of gender, age, and cardiac rhythm dis-orders. Morphological examination revealed the expression of spike SARS-CoV-2 in tumor cells, endothelial cells, and macrophages in 10 out of 11 heart tumors. Conclusion: The detection of SARS-CoV-2 persistence in endothelium and macrophages as well as in tumor cells of benign and malignant cardiac neoplasms, the increase in the number of these tumors, especially cardiac myxomas, after the pandemic by 2023 may indicate a trend toward an increased risk of cardiac neoplasms in COVID-19 patients, which re-quires further research on this issue and a search for new evidence.
format Online
Article
Text
id pubmed-10608002
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106080022023-10-28 High Risk of Heart Tumors after COVID-19 Mitrofanova, Lubov Makarov, Igor Goncharova, Ekaterina Makarova, Taiana Starshinova, Anna Kudlay, Dmitry Shlaykhto, Evgeny Life (Basel) Article An emergence of evidence suggests that severe COVID-19 is associated with an increased risk of developing breast and gastrointestinal cancers. The aim of this research was to assess the risk of heart tumors development in patients who have had COVID-19. Methods: A comparative analysis of 173 heart tumors was conducted between 2016 and 2023. Immunohistochemical examination with antibodies against spike SARS-CoV-2 was performed on 21 heart tumors: 10 myxomas operated before 2020 (the control group), four cardiac myxomas, one proliferating myxoma, three papillary fibroelastomas, two myxofibrosarcomas, one chondrosarcoma resected in 2022–2023. Immunohistochemical analysis with antibodies against CD34 and CD68 was also conducted on the same 11 Post-COVID period heart tumors. Immunofluorescent examination with a cocktail of antibodies against spike SARS-CoV-2/CD34 and spike SARS-CoV-2/CD68 was performed in 2 cases out of 11 (proliferating myxoma and classic myxoma). Results: A 1.5-fold increase in the number of heart tumors by 2023 was observed, with a statistically significant increase in the number of myxomas. There was no correlation with vaccination, and no significant differences were found between patients from 2016–2019 and 2021–2023 in terms of gender, age, and cardiac rhythm dis-orders. Morphological examination revealed the expression of spike SARS-CoV-2 in tumor cells, endothelial cells, and macrophages in 10 out of 11 heart tumors. Conclusion: The detection of SARS-CoV-2 persistence in endothelium and macrophages as well as in tumor cells of benign and malignant cardiac neoplasms, the increase in the number of these tumors, especially cardiac myxomas, after the pandemic by 2023 may indicate a trend toward an increased risk of cardiac neoplasms in COVID-19 patients, which re-quires further research on this issue and a search for new evidence. MDPI 2023-10-20 /pmc/articles/PMC10608002/ /pubmed/37895467 http://dx.doi.org/10.3390/life13102087 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mitrofanova, Lubov
Makarov, Igor
Goncharova, Ekaterina
Makarova, Taiana
Starshinova, Anna
Kudlay, Dmitry
Shlaykhto, Evgeny
High Risk of Heart Tumors after COVID-19
title High Risk of Heart Tumors after COVID-19
title_full High Risk of Heart Tumors after COVID-19
title_fullStr High Risk of Heart Tumors after COVID-19
title_full_unstemmed High Risk of Heart Tumors after COVID-19
title_short High Risk of Heart Tumors after COVID-19
title_sort high risk of heart tumors after covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608002/
https://www.ncbi.nlm.nih.gov/pubmed/37895467
http://dx.doi.org/10.3390/life13102087
work_keys_str_mv AT mitrofanovalubov highriskofhearttumorsaftercovid19
AT makarovigor highriskofhearttumorsaftercovid19
AT goncharovaekaterina highriskofhearttumorsaftercovid19
AT makarovataiana highriskofhearttumorsaftercovid19
AT starshinovaanna highriskofhearttumorsaftercovid19
AT kudlaydmitry highriskofhearttumorsaftercovid19
AT shlaykhtoevgeny highriskofhearttumorsaftercovid19